Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Net Cash Flow (2020 - 2025)

Gain Therapeutics has reported Net Cash Flow over the past 6 years, most recently at $11.9 million for Q4 2025.

  • Quarterly results put Net Cash Flow at $11.9 million for Q4 2025, up 1106.77% from a year ago — trailing twelve months through Dec 2025 was $10.0 million (up 1228.91% YoY), and the annual figure for FY2025 was $10.0 million, up 1228.91%.
  • Net Cash Flow for Q4 2025 was $11.9 million at Gain Therapeutics, up from $2.1 million in the prior quarter.
  • Over the last five years, Net Cash Flow for GANX hit a ceiling of $39.2 million in Q1 2021 and a floor of -$19.9 million in Q2 2022.
  • Median Net Cash Flow over the past 5 years was -$1.7 million (2023), compared with a mean of $642869.7.
  • Peak annual rise in Net Cash Flow hit 6065.83% in 2021, while the deepest fall reached 694.42% in 2021.
  • Gain Therapeutics' Net Cash Flow stood at -$4.2 million in 2021, then grew by 8.99% to -$3.8 million in 2022, then soared by 285.69% to $7.0 million in 2023, then plummeted by 116.83% to -$1.2 million in 2024, then skyrocketed by 1106.77% to $11.9 million in 2025.
  • The last three reported values for Net Cash Flow were $11.9 million (Q4 2025), $2.1 million (Q3 2025), and -$2.6 million (Q2 2025) per Business Quant data.